In the realm of biopharmaceuticals, the blood plasma derivatives market plays a crucial role in providing essential therapies for various medical conditions. Bovine blood plasma derivatives represent a significant segment within this market, offering valuable therapeutic options derived from cow's blood. These derivatives undergo a meticulous process of extraction and purification to isolate specific proteins and factors that possess therapeutic properties. From clotting factors to immunoglobulins, bovine blood plasma derivatives serve as vital components in the treatment of conditions such as hemophilia and immune deficiencies. Through advanced manufacturing techniques, these products are carefully developed to meet stringent quality standards, ensuring safety and efficacy for patients worldwide.
The Blood Plasma Derivatives Market size was valued at USD 41.55 billion in 2022 and is projected to grow from USD 46.96 Billion in 2023 to USD 95.66 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.41% during the forecast period (2023 - 2032).
Blood Plasma Derivatives Market: Latest Technological Developments
- In April 2023: The collaboration between CSL Behring and Takeda to create a potential plasma-derived therapeutic for COVID-19 treatment was announced. A novel technique termed "ultra-high-speed solvent detergent fractionation," which aims to create plasma derivatives that are more efficient and secure than conventional approaches, is being used to develop the therapy.
- In March 2023: A team of researchers from the University of California, San Francisco claimed that they have created a new, more effective and sustainable process for creating blood plasma derivatives. The procedure, known as "continuous flow plasma fractionation," is more effective than conventional techniques that involve batch processing because it separates plasma into its constituent elements using a continuous flow system.
- In February 2023: A company called Frontline Biotechnologies announced that the FDA has approved its first item, a blood plasma derivative known as "FrontlineODP," for commercialization. A dried plasma derivative called FrontlineODP is given to people with bleeding disorders.
Blood Plasma Derivatives Market: Recent News on Industry Investments
- In April 2023: A $1 billion investment round from investors including The Carlyle Group and CVC Capital Partners was disclosed by Grifols. The company intends to utilise the money to create new products and grow its network of plasma collection sites.
- In March 2023: According to an announcement by Octapharma AG, it has raised $500 million from investors that include KKR & Co. and The Carlyle Group. The money will be used by the business to increase production and create new goods.
- In February 2023: Kedrion S.p.A. declared that it had secured $250 million in capital from backers that included CVC Capital Partners and Bain Capital. The company intends to utilise the money to create new products and grow its network of plasma collection sites.
- Blood plasma derivatives are concentrates of specific plasma proteins derived from a pool of plasma donors through fractionation.
- They are crucial in treating various life-threatening diseases.
- Factors Driving Market Growth
- Prevalence of life-threatening blood-related diseases like hemophilia, cancer, HIV, etc., is increasing.
- Rise in global geriatric population, which is more prone to such diseases.
- Increasing awareness about blood and plasma donation.
- Advancements in preservation techniques of blood plasma.
- Significant investment in research & development activities.
- Expansion of clinical applications of blood plasma derivatives.
- Factors Restraining Market Growth
- High costs associated with plasma derivative-based therapies.
- Risk of adverse side effects from plasma replacement therapy.
- Segmentation
- Type: Includes anti-thrombin, fresh frozen plasma (FFP), intravenous immunoglobulin (IVIG), Albumin, Factor VII, Factor IX, Alpha 1 proteinase inhibitor concentrate, and others.
- Application: Covers Hemophilia A, Hemophilia B, HIV, Hepatitis B, Hepatitis C, Thrombocytosis, Von Willebrand disease, and others.
- End User: Encompasses blood transfusion centers, hospitals, diagnostic centers, clinics, and others.
- Regional Analysis
- North America: Dominates the market and is expected to expand at a CAGR of 4.25% over the forecast period. High awareness and affordability boost market growth.
- Europe: Second largest market driven by extensive R&D activities, expected to grow at a CAGR of 3.8%.
- Asia Pacific: Emerging as the fastest growing market due to growing prevalence of diseases and high awareness.
Blood fractionation products constitute another integral aspect of the blood plasma derivatives market, encompassing a diverse array of therapeutic substances derived from human plasma. Through the process of fractionation, plasma is separated into its constituent components, allowing for the isolation of various proteins and factors with therapeutic potential. These products include essential treatments such as albumin, immunoglobulins, and coagulation factors, which find applications in treating conditions ranging from autoimmune disorders to bleeding disorders. By harnessing the power of blood fractionation, biopharmaceutical companies produce a wide range of life-saving therapies that contribute significantly to patient care and disease management. The continued innovation and refinement of blood fractionation techniques drive advancements in the field of biomedicine, paving the way for improved treatments and outcomes for patients worldwide.
Competitive Landscape
Fusion Healthcare (India), Octapharma AG (Switzerland), Baxter International Inc. (US), Bain Capital, LLC (US), Grigols (Spain), Kedrion S.p.A (Italy), SK Plasma Co., Ltd. (South Korea), Biotest AG (Germany), and CSL Limited (Australia) are some of the prominent companies who are leading as the global blood plasma derivatives companies.
For more information visit at MarketResearchFuture
Other Trending Reports
